Han Joo Cho1, Tae Gon Lee2, Sang Youn Han1, Hyoung Seok Kim1, Jae Hui Kim1, Jung Il Han1, Young Ju Lew1, Jong Woo Kim1. 1. Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, 156, 4ga, Yeoungdeungpo-dong, Yeoungdeungpo-gu, Seoul, South Korea. 2. Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, 156, 4ga, Yeoungdeungpo-dong, Yeoungdeungpo-gu, Seoul, South Korea. idoc@kimeye.com.
Abstract
PURPOSE: To evaluate the long-term visual outcomes and investigate the prognostic factors of anti-vascular endothelial growth factor (VEGF) therapy for retinal angiomatous proliferation (RAP). METHODS: Thirty-eight treatment-naïve RAP eyes (38 patients) that received intravitreal anti-VEGF (ranibizumab and/or bevacizumab) injections were included and analyzed in this retrospective case series. All patients were treated with an initial series of three monthly intravitreal anti-VEGF injections, followed by as-needed injections for a total of 36 months. RESULTS: The mean number of anti-VEGF injections was 9.61 ± 3.1 during the 36-month follow-up. Mean baseline best-corrected visual acuity (BCVA) was 0.79 ± 0.56 logarithm of the minimum angle of resolution (logMAR; 20/123 Snellen equivalent), and 0.75 ± 0.41 logMAR (20/112 Snellen equivalent) at 36 months (P = 0.55). Mean BCVA significantly improved at 3 months (P = 0.001), and the significant improvement persisted until 18 months from baseline (P = 0.02). However, the mean BCVA between 18 and 36 months showed no statistical in comparison with baseline values. Geographic atrophy developed in 14 eyes (36.8 %) during the entire 36-month follow-up period. Among baseline characteristics, baseline BCVA, greatest lesion diameter (GLD), and lesion size were significantly correlated with long-term visual outcome (P = 0.008, 0.02, and 0.002 respectively). CONCLUSIONS: Intravitreal anti-VEGF injections for RAP showed a favorable visual outcome during the first year; however, the visual gains declined after the second year from baseline. Better baseline BCVA, smaller lesion size, and smaller baseline GLD are associated with better long-term visual outcomes in patients with RAP.
PURPOSE: To evaluate the long-term visual outcomes and investigate the prognostic factors of anti-vascular endothelial growth factor (VEGF) therapy for retinal angiomatous proliferation (RAP). METHODS: Thirty-eight treatment-naïve RAP eyes (38 patients) that received intravitreal anti-VEGF (ranibizumab and/or bevacizumab) injections were included and analyzed in this retrospective case series. All patients were treated with an initial series of three monthly intravitreal anti-VEGF injections, followed by as-needed injections for a total of 36 months. RESULTS: The mean number of anti-VEGF injections was 9.61 ± 3.1 during the 36-month follow-up. Mean baseline best-corrected visual acuity (BCVA) was 0.79 ± 0.56 logarithm of the minimum angle of resolution (logMAR; 20/123 Snellen equivalent), and 0.75 ± 0.41 logMAR (20/112 Snellen equivalent) at 36 months (P = 0.55). Mean BCVA significantly improved at 3 months (P = 0.001), and the significant improvement persisted until 18 months from baseline (P = 0.02). However, the mean BCVA between 18 and 36 months showed no statistical in comparison with baseline values. Geographic atrophy developed in 14 eyes (36.8 %) during the entire 36-month follow-up period. Among baseline characteristics, baseline BCVA, greatest lesion diameter (GLD), and lesion size were significantly correlated with long-term visual outcome (P = 0.008, 0.02, and 0.002 respectively). CONCLUSIONS: Intravitreal anti-VEGF injections for RAP showed a favorable visual outcome during the first year; however, the visual gains declined after the second year from baseline. Better baseline BCVA, smaller lesion size, and smaller baseline GLD are associated with better long-term visual outcomes in patients with RAP.
Authors: Alexandros A Rouvas; Irini P Chatziralli; Panagiotis G Theodossiadis; Marilita M Moschos; Athanasios I Kotsolis; Ioannis D Ladas Journal: Retina Date: 2012-06 Impact factor: 4.256
Authors: Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2009-04-18 Impact factor: 5.258
Authors: Juan E Grunwald; Ebenezer Daniel; Jiayan Huang; Gui-Shuang Ying; Maureen G Maguire; Cynthia A Toth; Glenn J Jaffe; Stuart L Fine; Barbara Blodi; Michael L Klein; Alison A Martin; Stephanie A Hagstrom; Daniel F Martin Journal: Ophthalmology Date: 2013-09-29 Impact factor: 12.079
Authors: Anja Schlecht; Julian Wolf; Stefaniya Boneva; Gabriele Prinz; Barbara M Braunger; Peter Wieghofer; Hansjürgen Agostini; Günther Schlunck; Clemens Lange Journal: Int J Mol Sci Date: 2022-03-22 Impact factor: 5.923
Authors: Shan Liu; Antje K Biesemeier; Alexander V Tschulakow; Harsh V Thakkar; Sylvie Julien-Schraermeyer; Ulrich Schraermeyer Journal: Biol Open Date: 2020-06-11 Impact factor: 2.422